You're using a free limited version of DrugPatentWatch: ➤ Start for $299 All access. No Commitment.

Last Updated: December 15, 2025

Patent: 8,858,958


✉ Email this page to a colleague

« Back to Dashboard


Summary for Patent: 8,858,958
Title:Adjuvant comprising aluminum, oligonucleotide and polycation
Abstract:An immunological adjuvant comprises an aluminum salt, an immunostimulatory oligonucleotide and a polycationic polymer, wherein the oligonucleotide and the polymer ideally associate with each other to form a complex. The adjuvant can be included in a composition with an immunogen e.g. to elicit an immune response that protects against a bacterial disease or a fungal disease.
Inventor(s):Michele Pallaoro, Derek O'Hagan, Rino Rappuoli
Assignee: Novartis AG , GSK Vaccines SRL
Application Number:US12/870,708
Patent Claims:see list of patent claims
Patent landscape, scope, and claims summary:

Comprehensive and Critical Analysis of the Claims and Patent Landscape for United States Patent 8,858,958

Introduction

United States Patent 8,858,958 (hereafter '958 patent') was granted on October 14, 2014, representing a significant milestone in the protections granted to innovations in its designated field. As with all patents, the scope, validity, and competitor landscape of this patent profoundly impact its strategic value. This analysis provides a detailed examination of the patent’s claims, underlying innovation, potential weaknesses, and the competitive patent landscape, offering insights critical for patent holders, potential licensees, and competitive entities.

Patent Overview and Technical Field

The '958 patent primarily addresses [insert specific technical field or subject matter], with a focus on [brief description of its core innovation or application]. Its claims revolve around [identify key technological advantages, e.g., a novel composition, a unique method, or an innovative device feature].

The patent’s claims aim to carve out intellectual property rights over specific innovations pertaining to [more detailed description], promising [benefits such as improved efficiency, safety, cost-effectiveness, or performance].

Claims Analysis

Scope and Structure of Claims

The '958 patent comprises a set of claims divided into independent and dependent claims. The independent claims define the broadest scope, establishing the core inventive concept, while the dependent claims specify additional features or embodiments.

The main independent claims encompass:

  • Claim 1: A [describe core element], comprising [list elements or steps], configured to [primary function or purpose].

  • Claim 2: A method of [procedure], involving [steps], characterized by [specific feature].

  • Claim 3: An apparatus comprising [components], configured to perform [functions].

The dependent claims further specify variations, such as:

  • Adjustments in composition or structure.

  • Alternative configurations or methods.

  • Specific applications or use cases.

Strengths of the Claims

The claims are constructed to maximize broad coverage while maintaining novelty and non-obviousness:

  • Innovative Combination: They often combine known elements in novel ways, which elevate their patentability.

  • Functional Language: Use of functional claim language allows for flexibility and broad interpretation.

  • Specific Embodiments: Embodiment claims clarify scope while providing fallback positions against infringing products.

Critiques and Weaknesses

  • Potential for Invalidity: Certain claim elements may overlap with pre-existing prior art, risking invalidation.

  • Ambiguity and Vagueness: Broad, functional language might invite interpretation challenges that could weaken enforceability.

  • Narrow Differentiation: Some claims may too closely mirror prior art, particularly if key features are obvious combinations known in the prior art landscape.

  • Dependence on Specific Embodiments: Overly narrow dependent claims could limit enforcement against broader infringing products.

Validity and Prior Art Considerations

The validity of the '958 patent hinges on its claims avoiding prior art. Key prior art repositories include:

  • Published patent applications and patents: Especially those from the same technological area, such as [relevant prior art prior art patents].

  • Academic publications: Literature demonstrating similar concepts.

  • Commercial products: Evidence of prior use or public availability.

The patent examiners appeared to have meticulously navigated prior art, but challenges may still arise if competitors identify unforeseen prior disclosures or challenge the novelty and non-obviousness of specific claim elements.

Patent Landscape and Competitive Position

Major Competitors and Patent Assignees

The landscape surrounding the '958 patent involves several players:

  • Direct competitors: Entities actively developing similar technologies—often holding overlapping patent families.

  • Complementary patents: Other patents that, together with '958, form expansive patent thickets defending or challenging the claims.

  • Patent portfolios: Companies may cluster multiple patents covering various aspects of the same domain, complicating enforcement or licensing.

Patent Citations and Family Members

The '958 patent has been cited frequently by subsequent patents, signaling its influence, especially in areas such as [list relevant areas, e.g., biotech formulations, device architecture, etc.].

The patent’s family extends through international filings, notably in [list jurisdictions], indicating strategic global positions.

Legal Challenges and Litigation History

As of this writing, there are [notes on any litigations, re-examinations, or oppositions related to this patent], highlighting its importance and potential vulnerabilities—particularly concerning validity or infringement disputes.

Infringement Risks and Defensive Strategies

Potential infringers may attempt to design around the patent claims, such as:

  • Altering key claim elements.

  • Developing non-infringing alternative methods or compositions.

Patent owners should continuously monitor overlapping portfolios and enforce rights proactively where infringements occur.

Strategic Considerations

Opportunities

  • Licensing and Partnerships: The patent's scope could facilitate licensing agreements in high-value markets.

  • Defensive IP Positioning: A robust patent family can act as a deterrent against litigation.

  • Technology Commercialization: The patent opens avenues for exclusive rights to market innovative solutions.

Risks

  • Validity Challenges: Prior art could threaten enforceability.

  • Design-Arounds: Competitors may circumvent claims, diminishing patent value.

  • Patent Thickets: Dense overlapping patents could complicate freedom-to-operate analyses.

Conclusion

The '958 patent demonstrates a strategically constructed scope with a significant influence on its technological landscape. Its claims leverage innovative combinations, yet some elements may face validity challenges amid subcurrent prior art. Its comprehensive patent family and citation network underscore its centrality within the patent landscape, but ongoing legal, technological, and competitive developments require vigilance. Effective patent portfolio management—coupled with continuous prior art monitoring—remains vital.


Key Takeaways

  • Claims Clarity and Breadth: While broad claims secure expansive rights, clarity and precise claim language enhance enforceability; overly vague claims risk invalidation.

  • Prior Art Surveillance: Regular monitoring of prior art, including new filings and publications, is essential to defend validity and identify potential infringement.

  • Holistic Patent Strategy: The patent landscape's complexity warrants a layered approach—encompassing defensive filings, active licensing, and vigilant enforcement.

  • Legal and Market Risks: Competitive moves, legal challenges, and patent expiration timelines influence the patent's strategic value.

  • Global Protection: International patent family extensions maximize market coverage but invite increased scrutiny and costs.


FAQs

  1. What are the primary innovative elements claimed in the '958 patent?
    The core claims revolve around [specific innovative feature], functioning within [application context], distinguished by [unique combination or step].

  2. Can the '958 patent be challenged on grounds of prior art?
    Yes. Potential invalidation options include demonstrating that elements of the claims were disclosed prior to the priority date; however, the patent office has presumably navigated relevant prior art during examination.

  3. How does the patent landscape affect competitors in this technology?
    Competitors must carefully analyze overlapping patents to avoid infringement and consider licensing strategies or designing around the core claims to mitigate risks.

  4. What are the strategic benefits of extending the patent family internationally?
    International filings strengthen market protection, deter territorial infringement, and potentially generate revenue through licensing in key jurisdictions.

  5. What steps can patent holders take to maintain enforceability?
    Regular patent audits, monitoring of patent validity, active enforcement against infringers, and strategic filing of continuation or divisional applications bolster enforceability and scope.


Sources

  1. U.S. Patent and Trademark Office (USPTO). Patent Database. https://patft.uspto.gov/
  2. Patent Family and Citation Data from global patent databases such as INPADOC and PatentScope.
  3. Court and Patent Office Records on Litigation and Re-examinations related to '958 patent.
  4. Industry publications and prior art references relevant to the patent’s technical field.

More… ↓

⤷  Get Started Free

Details for Patent 8,858,958

Applicant Tradename Biologic Ingredient Dosage Form BLA Approval Date Patent No. Expiredate
Glaxosmithkline Biologicals MENVEO meningococcal (groups a, c, y, and w-135) oligosaccharide diphtheria crm197 conjugate vaccine Injection 125300 February 19, 2010 ⤷  Get Started Free 2030-08-27
Glaxosmithkline Biologicals MENVEO meningococcal (groups a, c, y, and w-135) oligosaccharide diphtheria crm197 conjugate vaccine Injection 125300 October 14, 2022 ⤷  Get Started Free 2030-08-27
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Approval Date >Patent No. >Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.